Surgery for lung cancer should be carefully considered in patients who also have idiopathic pulmonary fibrosis (IPF), because it is associated with poor outcomes, a study shows. The study, “Survival after repeated surgery for lung cancer with idiopathic pulmonary fibrosis: a retrospective study,” was published in the journal…
News
Tiny extracellular vesicles that carry information from one cell to another may contribute to the development of idiopathic pulmonary fibrosis (IPF) by carrying molecules involved in the disease, a study has found. The study, “Increased Extracellular Vesicles Mediate WNT-5A Signaling in Idiopathic Pulmonary Fibrosis,” was published in the…
Lung cancer and acute exacerbations are significant predictors of mortality in patients with combined pulmonary fibrosis and emphysema, according to researchers. Their study, “Presence of lung cancer and high gender, age, and physiology score as predictors of acute exacerbation in combined pulmonary fibrosis and emphysema: A…
A recent study has provided more insight into the molecular processes that might be involved in the pathological changes that take place in the lungs of patients with idiopathic pulmonary fibrosis (IPF). In the study, “A role for telomere length and chromosomal damage in idiopathic pulmonary fibrosis,”…
Pliant Therapeutics announced that its lead therapy candidate PLN-74809 was designated an orphan drug by the U.S. Food and Drug Administration (FDA), an act that helps to advance its development as a possible treatment of…
Adding Ofev (nintedanib) to Esbriet (pirfenidone) for idiopathic pulmonary fibrosis (IPF) is tolerated by most patients and has a similar safety profile as taking each medication alone,…
The presence of swollen lymph nodes in patients with idiopathic pulmonary fibrosis (IPF) at the time of their diagnosis can be a predictor of poor prognosis, associated with stronger disease severity and lower survival, a study suggests.
Do NOX enzymes play a pivotal role in idiopathic pulmonary fibrosis (IPF)? This is the question researchers hope to answer with a newly funded research program evaluating the role of NOX enzymes. Genkyotex, a company focused on developing therapies for chronic diseases, recently announced that the U.S. National Institutes of…
The Pulmonary Fibrosis Foundation (PFF) has completed the enrollment of PF patients in its PFF Patient Registry, with the admission of the 2,002nd patient. Launched in 2016, the PFF Patient Registry was created to compile large quantities of data collected from anonymous PF patients, and use it to help…
A mechanism triggered by the activation of two specific proteins called JAK2 and STAT3 was found to contribute to the damaging cellular transformations that occur in idiopathic pulmonary fibrosis (IPF), a study reports. Blocking this signaling pathway reduced the levels of lung damage in a rat model of IPF,…
Your PF Community
Recent Posts
- Starting the year with a vision of wellness and a plan to follow through January 15, 2026
- New trial data show oral therapy alters immune pathways in adults with IPF January 14, 2026
- When you’re an IPF patient, the costs of care add up, but help is out there January 13, 2026
- Appearances can be deceptive for those living with pulmonary fibrosis January 13, 2026
- Gut bacteria B. adolescentis may be new preventive treatment for PF January 7, 2026
